Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet

Volumn 391, Issue 10139, 2018, Pages 2503-2512

  Burmester, Gerd R ^a   Kremer, Joel M ^b   Van den Bosch, Filip ^c,d   Kivitz, Alan ^e   Bessette, Louis ^f   Li, Yihan ^g   Zhou, Yijie ^g   Othman, Ahmed A ^g   Pangan, Aileen L ^g   Camp, Heidi S ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ALBANY MEDICAL COLLEGE   (United States)

^c GHENT UNIVERSITY   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e Altoona Center for Clinical Research   (United States)

^f UNIVERSITÉ LAVAL   (Canada)

^g ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CREATINE KINASE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE; UPADACITINIB; ANTIRHEUMATIC AGENT; JANUS KINASE INHIBITOR;

ADULT; ANEMIA; ARTICLE; CONTROLLED STUDY; DAS28; DIGESTIVE SYSTEM PERFORATION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEADACHE; HERPES ZOSTER; HUMAN; LIVER DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VENOUS THROMBOEMBOLISM; AGED; CLINICAL TRIAL; DISEASE EXACERBATION; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JANUS KINASE INHIBITORS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 85048339448     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31115-2     Document Type: Article

References (29)

1. Smolen, JS, Breedveld, FC, Burmester, GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75 (2016), 3–15.
2. van der Heijde, D, Keystone, EC, Curtis, JR, et al. Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. J Rheumatol 39 (2012), 1326–1333.
3. Aletaha, D, Funovits, J, Keystone, EC, Smolen, JS, Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 56 (2007), 3226–3235.
4. Singh, JA, Saag, KG, Bridges, SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68 (2016), 1–26.
5. Smolen, JS, Landewe, R, Bijlsma, J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76 (2017), 960–977.
6. Burmester, GR, Pope, JE, Novel treatment strategies in rheumatoid arthritis. Lancet 389 (2017), 2338–2348.
7. Burmester, GR, Blanco, R, Charles-Schoeman, C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381 (2013), 451–460.
8. Genovese, MC, Kremer, J, Zamani, O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374 (2016), 1243–1252.
9. Kavanaugh, A, Kremer, J, Ponce, L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis 76 (2017), 1009–1019.
10. Westhovens, R, Taylor, PC, Alten, R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 76 (2016), 998–1008.
11. Kremer, JM, Emery, P, Camp, HS, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol 68 (2016), 2867–2877.
12. Genovese, MC, Smolen, JS, Weinblatt, ME, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol 68 (2016), 2857–2866.
13. Mohamed, ME, Zeng, J, Marroum, P, Song, IH, Othman, AA, Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. Clin Pharmacol Drug Dev, 2018 published online April 24. DOI:10.1002/cpdd.462.
14. Aletaha, D, Neogi, T, Silman, AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69 (2010), 1580–1588.
15. Felson, DT, Anderson, JJ, Boers, M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995), 727–735.
16. Wells, G, Becker, JC, Teng, J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 68 (2009), 954–960.
17. Bykerk, VP, Massarotti, EM, The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford) 51:suppl 6 (2012), 16–20.
18. Anderson, JK, Zimmerman, L, Caplan, L, Michaud, K, Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken) 63:suppl 11 (2011), S14–S36.
19. Woodworth, T, Furst, DE, Alten, R, et al. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0. J Rheumatol 34 (2007), 1401–1414.
20. NCI. Common Terminology Criteria for Adverse Events, version 4.0. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. (Accessed 26 February 2018)
21. Bretz, F, Maurer, W, Brannath, W, Posch, M, A graphical approach to sequentially rejective multiple test procedures. Stat Med 28 (2009), 586–604.
22. Dossing, A, Tarp, S, Furst, DE, et al. Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol. BMJ Open, 4, 2014, e005297.
23. Klunder, B, Mohamed, MF, Othman, AA, Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials. Clin Pharmacokinet, 2017 published online 26. DOI:10.1007/s40262-017-0606-6.
24. Dougados, M, van der Heijde, D, Chen, YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76 (2017), 88–95.
25. Kremer, J, Li, ZG, Hall, S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159 (2013), 253–261.
26. da Silva, JA, Phillips, S, Buttgereit, F, Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis. Scand J Rheumatol Suppl 125 (2011), 6–11.
27. Genovese, MC, Fleischmann, R, Combe, B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet, 2018 published online June 13. http://dx.doi.org/10.1016/S0140-6736(18)31116-4.
28. O'Shea, JJ, Schwartz, DM, Villarino, AV, Gadina, M, McInnes, IB, Laurence, A, The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66 (2015), 311–328.
29. Cohen, SB, Tanaka, Y, Mariette, X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76 (2017), 1253–1262.